TP53 co‐mutation can negatively affect the efficacy of EGFR‐TKI in advanced NSCLC and was one of the potential biomarkers found in the biomarker analysis of the ADJUVANT/CTONG1104 study. Here, EGFR is linked to non-small cell lung carcinoma.